Holen Sie sich die Stockscreener-App
4.75
0.85%
0.05
Schlusskurs vom Vortag:
$4.70
Offen:
$4.82
24-Stunden-Volumen:
142.74K
Relative Volume:
0.40
Marktkapitalisierung:
$377.51M
Einnahmen:
$12.14M
Nettoeinkommen (Verlust:
$-99.50M
KGV:
-3.5089
EPS:
-1.3537
Netto-Cashflow:
$-56.37M
1W Leistung:
+4.87%
1M Leistung:
+36.99%
6M Leistung:
+169.32%
1J Leistung:
+434.14%
1-Tages-Spanne:
$4.50
$4.92
1-Wochen-Bereich:
$4.04
$5.26
52-Wochen-Spanne:
$0.73
$5.54
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Firmenname
Prelude Therapeutics Inc
Sektor
Branche
Telefon
(302) 467-1280
Adresse
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
4.74 | 374.32M | 12.14M | -99.50M | -56.37M | -1.3537 |
VRTX
Vertex Pharmaceuticals Inc
|
426.20 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
709.00 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
800.70 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.67 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.01 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-19 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2024-03-13 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-02-20 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | Eingeleitet | Jefferies | Buy |
| 2022-03-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-02-28 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-10-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-04-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-09 | Eingeleitet | Barclays | Overweight |
| 2020-11-20 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-10-20 | Eingeleitet | BofA Securities | Buy |
| 2020-10-20 | Eingeleitet | Goldman | Neutral |
| 2020-10-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Prelude Therapeutics Inc Aktie (PRLD) Neueste Nachrichten
Prelude Therapeutics (PRLD) price target increased by 19.35% to 6.29 - MSN
Prelude Therapeutics (PRLD) Presents Preclinical Data for KAT6A Degarader PRT13722 in Breast Cancer - Yahoo Finance
Prelude Therapeutics (NASDAQ:PRLD) Rating Increased to Hold at Zacks Research - MarketBeat
Prelude Therapeutics (NASDAQ: PRLD) outlines 2026 proxy votes on directors, pay and auditor - Stock Titan
Short Interest in Prelude Therapeutics Incorporated (NASDAQ:PRLD) Decreases By 22.1% - MarketBeat
HC Wainwright Issues Positive Estimate for PRLD Earnings - MarketBeat
RA Capital reports 7.88M-share Prelude Therapeutics (PRLD) stake - Stock Titan
Prelude Therapeutics (PRLD) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
H.C. Wainwright raises Prelude Therapeutics price target to $8 By Investing.com - Investing.com Canada
PRLD Maintained by HC Wainwright & Co. -- Price Target Raised to $8 - GuruFocus
HC Wainwright Issues Positive Forecast for Prelude Therapeutics (NASDAQ:PRLD) Stock Price - MarketBeat
Prelude Therapeutics (NASDAQ:PRLD) Director David Bonita Buys 2,815,315 Shares - MarketBeat
Prelude Therapeutics (NASDAQ:PRLD) Director Buys $12,499,998.60 in Stock - MarketBeat
Insider Purchase: Director at $PRLD Buys 1,689,189 Shares - Moomoo
Orbimed entities acquire $12.5m in Prelude Therapeutics stock By Investing.com - Investing.com Canada
Prelude Therapeutics director David P. Bonita acquires $12.5 million in stock - Investing.com
Prelude Therapeutics director David P. Bonita acquires $12.5 million in stock By Investing.com - Investing.com South Africa
Orbimed entities acquire $12.5m in Prelude Therapeutics stock - Investing.com
OrbiMed funds add Prelude Therapeutics (PRLD) shares at $4.44 in offering - Stock Titan
OrbiMed funds boost Prelude Therapeutics (NASDAQ: PRLD) stake with 2.82M-share buy - Stock Titan
Prelude Therapeutics Enters Underwriting for $85.5 Million Equity Offering Led by RA Capital - TradingView
Prelude Therapeutics (PRLD) Unveils Promising Preclinical Data f - GuruFocus
Prelude Therapeutics (PRLD) Launches $90M Public Offering with S - GuruFocus
Prelude Therapeutics Shares Rise on Positive Preclinical Data for Breast Cancer Drug - Moomoo
Prelude Therapeutics Unveils Promising Preclinical Data for First-in-Class Oral KAT6A Degrader PRT13722 in HR+/HER2- Breast Cancer at AACR 2026 12 - Minichart
Prelude Therapeutics prices $90M equity offering - MSN
Prelude Therapeutics prices $90M stock offering at $4.44/share By Investing.com - Investing.com Canada
Prelude Therapeutics presents preclinical data on breast cancer drug By Investing.com - Investing.com Canada
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering - ChartMill
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026 - Yahoo Finance
Prelude Therapeutics names Charles Morris as chief medical officer By Investing.com - Investing.com Australia
Prelude Therapeutics Appoints Dr. Charles Morris as Chief Medical Officer to Advance Precision Oncology Pipeline - Minichart
Prelude Therapeutics (PRLD) Appoints New Chief Medical Officer - GuruFocus
Prelude Therapeutics Appoints Veteran Oncologist as New CMO - TipRanks
Prelude Therapeutics names Charles Morris as chief medical officer - Investing.com
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer - The Manila Times
New CMO joins Prelude Therapeutics (NASDAQ: PRLD) as pipeline advances - Stock Titan
Bull Bear: Is Prelude Therapeutics Incorporated stock a good pick for beginners2026 Stock Rankings & Capital Efficiency Focused Ideas - baoquankhu1.vn
Activity Recap: Whats the beta of Prelude Therapeutics Incorporated stockQuarterly Trade Report & Safe Capital Investment Plans - baoquankhu1.vn
Aug Swings: What is the Moat Score of Prelude Therapeutics Incorporated2026 Earnings Impact & Weekly Stock Breakout Alerts - baoquankhu1.vn
Prelude Therapeutics (NASDAQ:PRLD) Shares Up 4.3%Still a Buy? - MarketBeat
Retail Surge: Is Prelude Therapeutics Incorporated a turnaround story2026 Drop Watch & Consistent Income Trade Recommendations - baoquankhu1.vn
PRLD Technical Analysis | Trend, Signals & Chart Patterns | PRELUDE THERAPEUTICS INC (NASDAQ:PRLD) - ChartMill
Loss Report: How do insiders feel about Prelude Therapeutics IncorporatedExit Point & Scalable Portfolio Growth Methods - baoquankhu1.vn
IPO Launch: Will Prelude Therapeutics Incorporated stock go up in YEARMarket Performance Recap & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Is Prelude (PRLD) Stock Declining | Price at $4.08, Down 7.27%Continuation Signals - Newser
Prelude Therapeutics Incorporated (PRLD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Prelude Therapeutics reports 2025 results and advances oncology pipeline - MSN
PRLD Technical Analysis & Stock Price Forecast - Intellectia AI
Rate Hike: Is Prelude Therapeutics Incorporated backed by strong institutional buying2026 Drop Watch & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Finanzdaten der Prelude Therapeutics Inc-Aktie (PRLD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.83%
2.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):